Gilead said PSI-7977 will be more valuable in its hands because it has the infrastructure to bring the product to more people faster than Pharmasset.
Gilead spent $11B on acquiring Pharmasset to get PSI-7977.
The PSI-7977 patent runs out in 2029.
2028, page-5
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)